Cystatin C-based AKI Staging in Critically Ill Patients: Methodological Concerns and Clinical Caveats From a Nephrology Perspective
Meng Li, Zhining Mo · 2026
Read Cystatin C-based AKI Staging in Critically Ill Patients: Methodological Concerns and Clinical Caveats From a Nephrology Perspective by Meng Li, Zhining Mo (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13499163.txt.
Description
Meng Li and Zhining Mo write in 2026 as kidney specialists responding to a proposed staging system for acute kidney injury based on a blood marker called cystatin C. The proposal reclassified many critically ill patients and predicted later death better than the usual marker. Writing to the journal editor, they welcome the aim of beating the older marker's limits while raising concerns that, in their view, block immediate bedside use.
One concern is that patients whose markers were falling were left out, which may inflate apparent risk and shrink how widely the system applies. Steroid drugs, common in intensive care for shock, raise cystatin C without true kidney decline and were not accounted for, which could mislabel patients. They also ask whether the new staging changes any real treatment choice, such as when to start dialysis, before it earns a place in practice.
Catalog record
| CREATOR | Meng Li, Zhining Mo |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3981 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |